After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori
You may also be interested in...
Fujifilm’s Sayonara To Dr. Reddy’s: Deal To Sell Generics In Japan Shelved
A high-profile joint venture between Fujifilm and Dr. Reddy’s to sell generic drugs in Japan has been terminated only two years after an initial MOU.
Lupin Adds Injectables Division In Japan with ¥3.1 Billion I'rom Pharmaceuticals Buyout
Lupin and I'rom also tie-up for Japanese clinical trial management as Indian firms see an improving generic drugs environment in Japan.
Top Japanese Pharmas Show Appetite For Emerging Market Expansion, Will Generics Follow?
TOKYO - Japanese pharma companies are trying to determine how to expand into new markets, ranging from the U.S. to China, and IMS Health data show a slow move away from dependence on the domestic market for Japan's leading companies